Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 prophylaxis in hemophilia A and B patients with inhibitors
CTR20234254Phase 3Active
- Sponsor
- Alphamab Oncology
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Feb 2024; status: active.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20234254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234254.